Amneal Pharmaceuticals (AMRX) News Today $8.26 -0.05 (-0.60%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Hennessy Advisors Inc.Hennessy Advisors Inc. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 6.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,670,600 shares of the company's stock after purchasinJanuary 17 at 8:25 AM | marketbeat.comAmneal receives FDA tentative approval for ANDA for rifaximinJanuary 17 at 2:40 AM | markets.businessinsider.comAmneal Pharmaceuticals backs prior FY24 EPS view 57c-63c, consensus 61cJanuary 16 at 4:32 PM | markets.businessinsider.comAmneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2024 Earnings GuidanceAmneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.570-0.630 for the period, compared to the consensus estimate of 0.610. The company also issued revenue guidance of $2.7 billionillion-$2.8 billionillion, compared to the consensus estimate of $2.8 billionillion.January 15 at 7:44 AM | marketbeat.comAmneal Pharmaceuticals Maintains Transparency with SEC FilingJanuary 15 at 6:55 AM | tipranks.comAnalysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $10.00January 14 at 1:45 AM | americanbankingnews.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 62,590 SharesJanuary 13, 2025 | americanbankingnews.comJPMorgan Chase & Co. Purchases 777,568 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)JPMorgan Chase & Co. raised its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 149.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,297,094 shares of the company'January 13, 2025 | marketbeat.comInsider Selling: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells 62,590 Shares of StockJanuary 11, 2025 | insidertrades.comGautam Patel Sells 62,590 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) StockAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director Gautam Patel sold 62,590 shares of the business's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total value of $501,345.90. Following the completion of the sale, the director now owns 1,968,886 shares in the company, valued at $15,770,776.86. The trade was a 3.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.January 10, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Moderate Buy" by AnalystsAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has received an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have isJanuary 9, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 17,410 SharesJanuary 7, 2025 | americanbankingnews.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells $139,454.10 in StockJanuary 7, 2025 | insidertrades.comGautam Patel Sells 17,410 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) StockAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director Gautam Patel sold 17,410 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the transaction, the director now directly owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. This represents a 0.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.January 6, 2025 | marketbeat.comHere’s Why Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Is Among the Best Diabetes Stocks to Buy Under $10January 6, 2025 | msn.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Quotes, Forecast and News SummaryJanuary 6, 2025 | benzinga.comJane Street Group LLC Has $681,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Jane Street Group LLC reduced its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 48.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 81,883 shares of the company's stock after seJanuary 4, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Decrease in Short InterestAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) saw a significant drop in short interest in December. As of December 15th, there was short interest totalling 3,540,000 shares, a drop of 24.2% from the November 30th total of 4,670,000 shares. Approximately 2.8% of the company's stock are sold short. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is currently 3.3 days.December 28, 2024 | marketbeat.comGeode Capital Management LLC Has $31.51 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Geode Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 11.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,786,671 shares ofDecember 26, 2024 | marketbeat.comBarclays PLC Purchases 169,756 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Barclays PLC boosted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 134.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,384 shares of the company's stock afteDecember 26, 2024 | marketbeat.comInvestors Buy High Volume of Amneal Pharmaceuticals Call Options (NASDAQ:AMRX)Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) saw some unusual options trading on Monday. Investors bought 2,563 call options on the stock. This represents an increase of approximately 719% compared to the typical daily volume of 313 call options.December 23, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by State Street CorpState Street Corp grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,514,721 shares of the company's stock after buying an additional 127,753December 22, 2024 | marketbeat.comWellington Management Group LLP Buys Shares of 82,596 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Wellington Management Group LLP purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 82,596 shares of the company's stock, valuedDecember 21, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Rating Lowered to "Buy" at StockNews.comStockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday.December 19, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 4.5% - Here's What HappenedAmneal Pharmaceuticals (NASDAQ:AMRX) Trading 4.5% Higher - What's Next?December 17, 2024 | marketbeat.comBNP Paribas Financial Markets Trims Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)BNP Paribas Financial Markets lowered its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 88.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,398 shares of the company's stock after sellingDecember 15, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. lowered its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 66.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97December 10, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Charles Schwab Investment Management Inc. lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 16.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,404,883 shDecember 9, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Amneal Pharmaceuticals (AMRX) and NextCure (NXTC)December 6, 2024 | markets.businessinsider.comWalleye Capital LLC Purchases Shares of 131,667 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Walleye Capital LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 131,667 shares of the company's stock, valued at approximately $1,095,000.December 6, 2024 | marketbeat.comPolar Asset Management Partners Inc. Purchases 216,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Polar Asset Management Partners Inc. lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 122.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 393,000 shareDecember 5, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Quantbot Technologies LPQuantbot Technologies LP lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 274.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,181 shares of the company'sDecember 2, 2024 | marketbeat.comAmneal resubmits DHE autoinjector NDA, gets FDA approval for exenatideNovember 22, 2024 | markets.businessinsider.comAmneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is ApprovedNovember 21, 2024 | marketwatch.comAmneal gets FDA approval for generic Byetta, resubmits DHE NDANovember 21, 2024 | msn.comAmneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistNovember 21, 2024 | businesswire.comGSA Capital Partners LLP Decreases Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)GSA Capital Partners LLP reduced its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 64.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,350 shares of the company's stockNovember 21, 2024 | marketbeat.comJason B. Daly Sells 43,657 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) StockNovember 20, 2024 | insidertrades.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Moderate Buy" by AnalystsAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has earned an average rating of "Moderate Buy" from the five research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating tNovember 20, 2024 | marketbeat.comPhocas Financial Corp. Reduces Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Phocas Financial Corp. decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 5.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,015,190 shares of the company'November 19, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 16.3% in OctoberAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 3,500,000 shares, a decrease of 16.3% from the October 15th total of 4,180,000 shares. Approximately 2.9% of the company's stock are short sold. Based on an average trading volume of 1,190,000 shares, the days-to-cover ratio is presently 2.9 days.November 15, 2024 | marketbeat.comAmneal Pharmaceuticals price target raised to $11 from $9 at Piper SandlerNovember 11, 2024 | markets.businessinsider.comAmneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High Following Analyst UpgradeAmneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year High on Analyst UpgradeNovember 11, 2024 | marketbeat.comPiper Sandler Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock PricePiper Sandler lifted their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday.November 11, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comAmneal Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Nisa Investment Advisors LLCNisa Investment Advisors LLC lowered its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 96.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 7,069 shares of the company's stock after selling 221,848 shares durNovember 9, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comAmneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60cNovember 8, 2024 | markets.businessinsider.comGeneric Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual ForecastsNovember 8, 2024 | finance.yahoo.com Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRX Media Mentions By Week AMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRX News Sentiment▼0.650.72▲Average Medical News Sentiment AMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRX Articles This Week▼114▲AMRX Articles Average Week Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ASND News Today ROIV News Today RVMD News Today LNTH News Today BPMC News Today BBIO News Today LEGN News Today ELAN News Today CYTK News Today NUVL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRX) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
